CorMedix (CRMD) Long-Term Deferred Tax (2015 - 2025)

CorMedix (CRMD) reported Long-Term Deferred Tax of $16.3 million for Q4 2025, down 69.0% sequentially from $52.5 million in Q3 2025.

CorMedix (CRMD) Long-Term Deferred Tax (2015 - 2025) Analysis & Trends

CorMedix (CRMD) has 7 years of Long-Term Deferred Tax data on file, last reported at $16.3 million in Q4 2025.

For the quarter ending Q4 2025, Long-Term Deferred Tax changed N/A year-over-year to $16.3 million; the trailing twelve-month figure through Dec 2025 stood at $16.3 million (changed N/A YoY), and the FY2025 full-year result was $16.3 million, changed N/A from the prior year.
Long-Term Deferred Tax declined to $16.3 million in Q4 2025, from $52.5 million in the prior quarter.
In the past five years, Long-Term Deferred Tax ranged from a high of $53.0 million in Q4 2021 to a low of $16.3 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	CorMedix	546.82 Mn	391.62 Mn	107.31 Mn

Download Data